Major histocompatibility complex class II antigen presentation machinery (MHC II machinery) (MHC II machinery)

The Major histocompatibility complex class II (MHC II) antigen presentation machinery is a multi-component system essential for the adaptive immune system's ability to recognize foreign pathogens. It primarily functions in professional antigen-presenting cells (APCs) like dendritic cells, macrophages, and B cells to process exogenous proteins into peptides and present them to CD4+ T-helper cells (Roche & Furuta, 2015). Key components include the MHC II alpha and beta chains (HLA-DR, HLA-DQ, HLA-DP), the invariant chain (CD74) which prevents premature peptide binding, and the HLA-DM chaperone which facilitates the exchange of the CLIP peptide for high-affinity antigenic peptides (Neefjes et al., 2011). This machinery is a critical checkpoint in immune activation; its overactivity is linked to autoimmune conditions such as rheumatoid arthritis and multiple sclerosis, while its downregulation is a common mechanism for tumor immune evasion (StatPearls, 2023). Drugs like glatiramer acetate target this system by competing for the MHC II binding groove, while others like hydroxychloroquine interfere with the endosomal pH required for proper processing (PubMed, 2021). Targeting this machinery allows for the modulation of T-cell-mediated immunity, though it carries risks of broad immunosuppression. Monoclonal antibodies targeting specific components like CD74 (e.g., milatuzumab) are also used to treat B-cell malignancies by exploiting the machinery's internalizing properties (UniProt, 2024). Overall, the MHC II machinery represents a complex but vital therapeutic landscape for managing immune-mediated diseases and cancer.

Other names

MHC class II pathwayHLA class II antigen presentation pathwayExogenous antigen presentation pathwayMHCII processing and presentation system

Inhibition of endosomal acidification to prevent peptide loading, competitive binding to the MHC II peptide-binding groove, and monoclonal antibody-mediated targeting of the invariant chain (CD74) or MHC II heterodimers to modulate T-cell activation.